

Ramunas Janavicius

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4202726/publications.pdf>

Version: 2024-02-01

59
papers

4,944
citations

147801

31
h-index

133252

59
g-index

63
all docs

63
docs citations

63
times ranked

7937
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathology of Breast and Ovarian Cancers among <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from the Consortium of Investigators of Modifiers of <i>BRCA1/2</i> (CIMBA). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 134-147.	2.5	513
2	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1347.	7.4	390
3	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
4	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	21.4	289
5	Cancer Risks Associated With Germline <i>PALB2</i> Pathogenic Variants: An International Study of 524 Families. <i>Journal of Clinical Oncology</i> , 2020, 38, 674-685.	1.6	270
6	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	21.4	265
7	Genome-Wide Association Study in <i>BRCA1</i> Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	3.5	244
8	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	2.5	224
9	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	21.4	221
10	Founder <i>BRCA1/2</i> mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. <i>EPMA Journal</i> , 2010, 1, 397-412.	6.1	193
11	Prediction of Breast and Prostate Cancer Risks in Male <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Using Polygenic Risk Scores. <i>Journal of Clinical Oncology</i> , 2017, 35, 2240-2250.	1.6	152
12	Breast cancer risk variants at 6q25 display different phenotype associations and regulate <i>ESR1</i> , <i>RMND1</i> and <i>CCDC170</i> . <i>Nature Genetics</i> , 2016, 48, 374-386.	21.4	125
13	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	21.4	120
14	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in <i>RAD51C</i> and <i>RAD51D</i> . <i>Journal of the National Cancer Institute</i> , 2020, 112, 1242-1250.	6.3	106
15	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016, 7, 11375.	12.8	93
16	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019, 10, 1741.	12.8	90
17	Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. <i>Journal of Clinical Oncology</i> , 2022, 40, 1529-1541.	1.6	90
18	Male breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: pathology data from the Consortium of Investigators of Modifiers of <i>BRCA1/2</i> . <i>Breast Cancer Research</i> , 2016, 18, 15.	5.0	88

#	ARTICLE	IF	CITATIONS
19	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	2.4	82
20	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	12.8	78
21	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2011, 13, R110.	5.0	71
22	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2011, 20, 3304-3321.	2.9	68
23	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2014, 16, 3416.	5.0	57
24	Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants. <i>JAMA Oncology</i> , 2020, 6, 1218.	7.1	48
25	Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 645-657.	2.5	47
26	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS Genetics</i> , 2014, 10, e1004256.	3.5	47
27	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. <i>Breast Cancer Research</i> , 2016, 18, 112.	5.0	42
28	Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2011, 103, 105-116.	6.3	40
29	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.9	39
30	Microsatellite Instability Detection by High-Resolution Melting Analysis. <i>Clinical Chemistry</i> , 2010, 56, 1750-1757.	3.2	35
31	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. <i>Human Mutation</i> , 2012, 33, 690-702.	2.5	34
32	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. <i>PLoS ONE</i> , 2015, 10, e0120020.	2.5	34
33	Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania. <i>Cancer Genetics</i> , 2014, 207, 195-205.	0.4	29
34	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, 61.	5.0	26
35	Exploring the link between MORF4L1 and risk of breast cancer. <i>Breast Cancer Research</i> , 2011, 13, R40.	5.0	23
36	A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1362-1370.	2.5	23

#	ARTICLE	IF	CITATIONS
37	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	2.8	23
38	ATL. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1395-1400.	2.5	22
39	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 308-316.	2.5	22
40	Identification and Functional Testing of ERCC2 Mutations in a Multi-national Cohort of Patients with Familial Breast- and Ovarian Cancer. <i>PLoS Genetics</i> , 2016, 12, e1006248.	3.5	22
41	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>British Journal of Cancer</i> , 2019, 121, 180-192.	6.4	19
42	Breast and Prostate Cancer Risks for Male <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2022, 114, 109-122.	6.3	19
43	No clinical utility of <i>KRAS</i> variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	1.4	18
44	Association of breast cancer risk in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 117-134.	2.5	18
45	A method to estimate cell cycle time and growth fraction using bromodeoxyuridine-flow cytometry data from a single sample. <i>BMC Cancer</i> , 2005, 5, 122.	2.6	17
46	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous <i>BRCA1</i> or <i>BRCA2</i> pathogenic variant. <i>Genetics in Medicine</i> , 2021, 23, 1726-1737.	2.4	16
47	Haplotype analysis and ancient origin of the <i>BRCA1</i> c.4035delA Baltic founder mutation. <i>European Journal of Medical Genetics</i> , 2013, 56, 125-130.	1.3	14
48	The Spectrum of <i>FANCM</i> Protein Truncating Variants in European Breast Cancer Cases. <i>Cancers</i> , 2020, 12, 292.	3.7	11
49	Novel and common <i>BRCA1</i> mutations in familial breast/ovarian cancer patients from Lithuania. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 467-469.	2.5	10
50	Novel germline <i>MSH2</i> mutation in lynch syndrome patient surviving multiple cancers. <i>Hereditary Cancer in Clinical Practice</i> , 2012, 10, 1.	1.5	10
51	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>PLoS ONE</i> , 2016, 11, e0158801.	2.5	10
52	Risks of breast and ovarian cancer for women harboring pathogenic missense variants in <i>BRCA1</i> and <i>BRCA2</i> compared with those harboring protein truncating variants. <i>Genetics in Medicine</i> , 2022, 24, 119-129.	2.4	10
53	Apparently <i>BRCA</i> -Related Breast and Ovarian Cancer Patient With Germline <i>TP53</i> Mutation. <i>Breast Journal</i> , 2011, 17, 409-415.	1.0	8
54	The incidence of occult ovarian neoplasia and cancer in <i>BRCA1/2</i> mutation carriers after the bilateral prophylactic salpingo-oophorectomy (PBSO): A single-center prospective study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 247, 26-31.	1.1	8

#	ARTICLE	IF	CITATIONS
55	Cumulative Small Effect Genetic Markers and the Risk of Colorectal Cancer in Poland, Estonia, Lithuania, and Latvia. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-10.	1.5	5
56	Extremely low risk of pheochromocytomas in complete VHL gene deletion cases. <i>Human Mutation</i> , 2009, 30, 1365-1366.	2.5	2
57	Overlapping Phenotype of Cardiomyopathy in a Patient with Double Mutation: A Case Report. <i>Neurology International</i> , 2021, 11, 31-38.	0.5	1
58	Multiple endocrine neoplasia type 1: a case report and review of the literature. <i>Open Medicine (Poland)</i> , 2014, 9, 424-430.	1.3	0
59	Identification of ERCC2 as novel susceptibility gene for hereditary breast and ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1512-1512.	1.6	0